2010
Antibody-Based Therapies for Solid Tumors
Shanbhag S, Burtness B. Antibody-Based Therapies for Solid Tumors. Cancer Growth And Progression 2010, 245-256. DOI: 10.1007/978-90-481-9704-0_13.Peer-Reviewed Original ResearchSide effectsHER2-overexpressing breast cancerStandard cytotoxic chemotherapyCell lung cancerEGFR antibody cetuximabAntibody-based therapiesExcess side effectsAnti-VEGF antibodyMechanism of actionMetastatic settingCytotoxic chemotherapyMetastatic colorectalLung cancerColorectal carcinomaBreast cancerAntibody cetuximabVEGF antibodySolid tumorsAntibody trastuzumabClinical useMonoclonal antibodiesCancer therapeuticsCancerAntibodiesBevacizumab
2007
Her signaling in pancreatic cancer
Burtness B. Her signaling in pancreatic cancer. Expert Opinion On Biological Therapy 2007, 7: 823-829. PMID: 17555368, DOI: 10.1517/14712598.7.6.823.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsCetuximabDeoxycytidineEpidermal Growth FactorErlotinib HydrochlorideGemcitabineHumansLapatinibOrganoplatinum CompoundsOxaliplatinPancreatic NeoplasmsProtein Kinase InhibitorsQuinazolinesReceptor, ErbB-2Signal TransductionTreatment OutcomeConceptsPhase II trialPhase III trialsPancreatic cancerEpidermal growth factor receptorII trialIII trialsRandomized phase II trialTreatment-refractory cancerManagement of patientsPhase I trialEGFR antibody cetuximabAddition of erlotinibGrowth factor receptorGemcitabine chemotherapyMedian survivalStandard therapyI trialPatient selectionSignificant prolongationMetastatic cancerAntibody cetuximabTherapeutic targetGemcitabineEGFR/Cancer